Rafferty Asset Management
TVTX icon

Rafferty Asset Management’s Travere Therapeutics TVTX Stock Holding History

Rafferty Asset Management’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.53M Sell
152,433
-16,775
-10% -$501K 0.02% 420
2025
Q4 		$6.47M Buy
169,208
+78,958
+87% +$2.57M 0.02% 348
2025
Q3 		$2.16M Sell
90,250
-33,604
-27% -$632K 0.01% 634
2025
Q2 		$1.83M Sell
123,854
-21,167
-15% -$351K 0.01% 621
2025
Q1 		$2.6M Sell
145,021
-31,404
-18% -$637K 0.01% 506
2024
Q4 		$3.07M Buy
176,425
+84,654
+92% +$1.5M 0.01% 517
2024
Q3 		$1.28M Sell
91,771
-90,521
-50% -$943K ﹤0.01% 743
2024
Q2 		$1.5M Sell
182,292
-412,940
-69% -$2.78M 0.01% 719
2024
Q1 		$4.59M Buy
595,232
+166,071
+39% +$1.4M 0.02% 491
2023
Q4 		$3.86M Buy
429,161
+67,168
+19% +$489K 0.02% 501
2023
Q3 		$3.24M Sell
361,993
-136,259
-27% -$1.92M 0.02% 484
2023
Q2 		$7.65M Buy
498,252
+171,782
+53% +$3.12M 0.04% 299
2023
Q1 		$7.34M Buy
326,470
+7,016
+2% +$149K 0.05% 273
2022
Q4 		$6.72M Buy
319,454
+113,687
+55% +$2.41M 0.06% 311
2022
Q3 		$5.07M Buy
205,767
+72,542
+54% +$1.87M 0.05% 335
2022
Q2 		$3.23M Sell
133,225
-28,018
-17% -$705K 0.03% 374
2022
Q1 		$4.16M Sell
161,243
-12,043
-7% -$320K 0.02% 422
2021
Q4 		$5.38M Buy
173,286
+73,364
+73% +$2.07M 0.03% 364
2021
Q3 		$2.42M Sell
99,922
-34,739
-26% -$638K 0.02% 580
2021
Q2 		$1.97M Buy
134,661
+36,783
+38% +$726K 0.01% 691
2021
Q1 		$2.44M Buy
97,878
+86,909
+792% +$2.4M 0.02% 573
2020
Q4 		$299K Sell
10,969
-29,575
-73% -$690K ﹤0.01% 811
2020
Q3 		$748K Buy
40,544
+23,314
+135% +$453K 0.01% 620
2020
Q2 		$352K Buy
+17,230
New +$274K 0.01% 792
2020
Q1 		– Sell
-46,425
Closed -$659K – 794
2019
Q4 		$659K Sell
46,425
-83,503
-64% -$1.07M 0.01% 643
2019
Q3 		$1.51M Buy
129,928
+63,622
+96% +$1.05M 0.02% 459
2019
Q2 		$1.33M Buy
66,306
+8,237
+14% +$163K 0.02% 502
2019
Q1 		$1.31M Buy
+58,069
New +$1.28M 0.02% 498

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Rafferty Asset Management's TVTX Position: Q1 2026 in Review

Rafferty Asset Management reduced its Travere Therapeutics (TVTX) stake by 9.9% in Q1 2026, selling an estimated $501K and leaving 152,433 shares worth $4.53M. The position accounts for 0.02% of the portfolio, ranked #420.

Rafferty Asset Management first reported a position in TVTX in Q1 2019 and has held it in 28 quarters since. The position peaked at $7.65M in Q2 2023. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • Rafferty Asset Management held 152,433 shares of Travere Therapeutics worth $4.53M as of Q1 2026.
  • Rafferty Asset Management sold 16,775 Travere Therapeutics shares in Q1 2026, an estimated $501K.
  • Travere Therapeutics made up 0.02% of Rafferty Asset Management's portfolio in Q1 2026, its #420 holding.
  • Rafferty Asset Management first reported a position in Travere Therapeutics in Q1 2019 and has held it in 28 quarters since.
  • Rafferty Asset Management's Travere Therapeutics position peaked at $7.65M in Q2 2023.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Rafferty Asset Management's 13F filing for Q1 2026, filed 15 May 2026.